PCOS – Long Term Consequences
Need For a Preventive Strategy

Dr. Piya Ballani Thakkar

Hyperandrogenism
Dyslipidemia
Reproductive dysfunction
Macrovascular complications
Central obesity
PCOS
Malignancies
Hypertension
Dyslipidemia

Diplomate of the American Board of Endocrinology, Diabetes & Metabolism
F.A.C.E.
Diplomate of the American Board of Int. Medicine
M.D. - Ob/ Gyn (Mumbai), D.N.B., D.G.O., F.C.P.S.

Consultant Endocrinologist
Bombay Hospital and Medical Research Center
PCOS

- PCOS is a heterogeneous disorder linked with disturbances of reproductive, endocrine and metabolic function.
- It is characterized by hyperandrogenism, ovulatory dysfunction, polycystic ovarian morphology, and insulin resistance.
- The disorder appears to be an ancient complex genetic trait
- Multifactorial and Polygenic
- Recognized as one of the most common endocrine abnormalities of humans, with global prevalences 5%-15%
PCOS Indian Scenario

- Studies conducted on Indian PCOS women suggested that abnormalities of the insulin receptor are more common in Indian women with PCOS compared to white women with PCOS.

- Adolescent obesity and PCOS individually and together have emerged as important public health issues in India.

- There is an urgent need to organize preventive strategy to the oncoming epidemics of obesity and obesity associated PCOS in India.

1. Ramanand SJ et al, Indian J Endocrinol Metab. 2013 Jan-Feb; 17(1): 138–145
PCOS Continuum

IR is Underlying problem at each stage

- **Puberty**
  - Irregular periods
  - Acne
  - Hirsuitism
  - Obesity

- **Reproductive Age**
  - Infertility
  - GDM

- **Middle Age**
  - Increased risk of developing T2 DM, CVD & other Metabolic disorders

- **Post menopause**
  - Metabolic disorders
  - Cancer
  - CVD
INSULIN RESISTANCE IN PCOS

INTRINSIC / EXTRINSIC

• INSULIN RESISTANCE IS INTRINSIC TO PCOS

• IT PLAYS A CENTRAL ROLE IN THE PATHOGENESIS OF PCOS AS INSULIN-INDUCED HYPERANDROGENAEMIA IS THE UNDERLYING BIOCHEMICAL ABNORMALITY IN PCOS

• IT IS INDEPENDENT OF OBESITY (30% OF PCOS WOMEN ARE NOT OBESE)

• OBESITY WHEN PRESENT (de novo OR AS A RESULT OF INTRINSIC IR) IS AN EXTRINSIC CAUSE OF IR IN PCOS.

• PCOS is an IR Syndrome,
• a gender-specific form of Metabolic Syndrome,
• hence also called “Syndrome XX”
Insulin levels in PCOS

Dunaif
Insulin sensitivity is reduced in lean and obese women with PCOS

Robinson et al, Clin Endocrinol 1992 36 537
Twins

Insulin Resistance

Hyper androgenemia

T2DM
HT
MetS

Hirsutism
Acne
Alopecia

Metabolic symptoms
Cosmetic symptoms

Abbreviations: T2DM, type 2 diabetes mellitus; HT, hypertension; MetS, metabolic syndrome.
TISSUE SPECIFIC EFFECTS OF INSULIN RESISTANCE IN PCOS

**INSULIN RESISTANT**
- MUSCLE
  - Glucose Uptake
  - IGT DM
- ADIPOSE
  - Lipolysis
  - DYSLIPIDAEMIA

**INSULIN SENSITIVE**
- OVARY
  - ANDROGEN PRODUCTION
  - SHBG PRODUCTION
- ADRENAL
- LIVER
- PILO – SEBACEOUS UNIT
  - PROLIFERATION
PCOS - Beginning of Long Term Non-Communicable Diseases

- Increased risk of developing Type 2 Diabetes and Gestational diabetes
- Low HDL and high triglycerides
- Sleep apnea (30 fold higher)
- Nonalcoholic steatohepatitis
- Metabolic syndrome—43% of PCOS patients (2 fold higher than age-matched population)
- Elevated CRP and CV risk
- Malignancy risk (3 fold)
- Depression
Glucose Intolerance/ Diabetes in PCOS

Figure 1.
Women with PCOS (black bars) had much higher prevalence of abnormal glucose tolerance compared to control women of similar ethnicity, age, and weight (gray bars) (P=0.02) as well as compared to reproductive-age women from the Second National Health and Nutrition Examination Survey (NHANES) (white bars).4

Legro et al, 1999, JCEM

n=254
IGT - Risk in women with PCOS

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>PCOS Events</th>
<th>PCOS Total</th>
<th>Control Events</th>
<th>Control Total</th>
<th>Weight (%)</th>
<th>Odds Ratio M-H, Fixed, 95% CI</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dos Reis 1995</td>
<td>7</td>
<td>29</td>
<td>0</td>
<td>19</td>
<td>1.9%</td>
<td>13.00 [0.70, 242.54]</td>
<td>1995</td>
</tr>
<tr>
<td>Rajkhowa 1996</td>
<td>10</td>
<td>72</td>
<td>1</td>
<td>39</td>
<td>4.6%</td>
<td>6.13 [0.75, 49.80]</td>
<td>1996</td>
</tr>
<tr>
<td>Yarali 2001</td>
<td>1</td>
<td>30</td>
<td>0</td>
<td>30</td>
<td>2.0%</td>
<td>3.10 [0.12, 79.23]</td>
<td>2001</td>
</tr>
<tr>
<td>Dunaif 2001</td>
<td>3</td>
<td>12</td>
<td>0</td>
<td>12</td>
<td>1.5%</td>
<td>9.21 [0.42, 200.59]</td>
<td>2001</td>
</tr>
<tr>
<td>Phy 2004</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>18</td>
<td>2.0%</td>
<td>10.67 [1.31, 86.93]</td>
<td>2004</td>
</tr>
<tr>
<td>Faloia 2004</td>
<td>3</td>
<td>50</td>
<td>1</td>
<td>20</td>
<td>5.5%</td>
<td>1.21 [0.12, 12.40]</td>
<td>2004</td>
</tr>
<tr>
<td>Diamanti-Kandarakis 2005</td>
<td>1</td>
<td>29</td>
<td>0</td>
<td>22</td>
<td>2.2%</td>
<td>2.37 [0.09, 60.96]</td>
<td>2005</td>
</tr>
<tr>
<td>Alvarez-Blasco 2006</td>
<td>4</td>
<td>32</td>
<td>8</td>
<td>72</td>
<td>17.8%</td>
<td>1.14 [0.32, 4.11]</td>
<td>2006</td>
</tr>
<tr>
<td>Leibel 2006</td>
<td>3</td>
<td>36</td>
<td>0</td>
<td>21</td>
<td>2.3%</td>
<td>4.49 [0.22, 91.35]</td>
<td>2006</td>
</tr>
<tr>
<td>Echiburu 2008</td>
<td>17</td>
<td>159</td>
<td>1</td>
<td>93</td>
<td>4.7%</td>
<td>11.01 [1.44, 84.18]</td>
<td>2008</td>
</tr>
<tr>
<td>Bhattacharya 2009</td>
<td>32</td>
<td>264</td>
<td>11</td>
<td>116</td>
<td>55.5%</td>
<td>1.32 [0.84, 2.71]</td>
<td>2009</td>
</tr>
</tbody>
</table>

Total (95% CI) | 720 | 462 | 100.0% | 2.61 [1.62, 4.20]

Total events | 85 | 24

Heterogeneity: Chi² = 11.69, df = 10 (P = 0.31); I² = 14%
Test for overall effect: Z = 3.94 (P < 0.0001)

Risk of IGT in PCOS OR: 2.61 [1.62, 4.20]

Moran et al, 2010, Human Reprod Update
Type 2 Diabetes - Risk in PCOS

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Events</th>
<th>Total</th>
<th>Control</th>
<th>Events</th>
<th>Total</th>
<th>Weight</th>
<th>M-H, Fixed, 95% CI</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dos Reis 1995</td>
<td>3</td>
<td>29</td>
<td>0</td>
<td>19</td>
<td>19</td>
<td>5.15</td>
<td>[0.25, 105.59]</td>
<td>1995</td>
</tr>
<tr>
<td>Rajkhowa 1996</td>
<td>2</td>
<td>72</td>
<td>0</td>
<td>39</td>
<td>39</td>
<td>2.80</td>
<td>[0.13, 59.82]</td>
<td>1996</td>
</tr>
<tr>
<td>Cibula 2000</td>
<td>9</td>
<td>28</td>
<td>60</td>
<td>752</td>
<td></td>
<td>5.46</td>
<td>[2.37, 12.60]</td>
<td>2000</td>
</tr>
<tr>
<td>Sir-Petermann 2004</td>
<td>4</td>
<td>146</td>
<td>0</td>
<td>97</td>
<td>97</td>
<td>6.16</td>
<td>[0.33, 115.68]</td>
<td>2004</td>
</tr>
<tr>
<td>Leibel 2006</td>
<td>3</td>
<td>36</td>
<td>0</td>
<td>21</td>
<td>21</td>
<td>4.49</td>
<td>[0.22, 91.35]</td>
<td>2006</td>
</tr>
<tr>
<td>Alvarez-Blasco 2006</td>
<td>0</td>
<td>32</td>
<td>3</td>
<td>72</td>
<td>72</td>
<td>0.31</td>
<td>[0.02, 6.09]</td>
<td>2006</td>
</tr>
<tr>
<td>Marquez 2008</td>
<td>6</td>
<td>50</td>
<td>3</td>
<td>70</td>
<td>70</td>
<td>3.05</td>
<td>[0.72, 12.82]</td>
<td>2008</td>
</tr>
<tr>
<td>Attuoua 2008</td>
<td>17</td>
<td>107</td>
<td>5</td>
<td>100</td>
<td>100</td>
<td>3.59</td>
<td>[1.27, 10.13]</td>
<td>2008</td>
</tr>
<tr>
<td>Shaw 2008</td>
<td>34</td>
<td>104</td>
<td>70</td>
<td>286</td>
<td></td>
<td>1.50</td>
<td>[0.92, 2.45]</td>
<td>2008</td>
</tr>
<tr>
<td>Moini 2009</td>
<td>4</td>
<td>273</td>
<td>0</td>
<td>276</td>
<td>276</td>
<td>9.23</td>
<td>[0.49, 172.33]</td>
<td>2009</td>
</tr>
<tr>
<td>Bhattacharya 2009</td>
<td>11</td>
<td>264</td>
<td>2</td>
<td>116</td>
<td>116</td>
<td>2.48</td>
<td>[0.54, 11.36]</td>
<td>2009</td>
</tr>
</tbody>
</table>

Subgroup analysis (BMI-matched studies only)

Risk of DM2 in PCOS: OR 3.66 [1.98, 6.75]

Moran et al, 2010, Human Reprod Update
PCOS and pregnancy complications

**Gestational diabetes: OR 3.66 (95% CI 1.20 – 11.16)**

Figure 1. Odds ratio (OR) for incidence of gestational diabetes mellitus (GDM) comparing women with polycystic ovary syndrome (PCOS) versus controls.

Boomsma et al. Hum Reprod Upd 2006
Who is at risk of T2D?

- PCOS (2-fold)
- PCOS + obesity (3-fold)
- PCOS + obesity + FH of diabetes
- PCOS + obesity + GDM
- PCOS + obesity + IGT
Making The Diagnosis

Supportive of insulin resistance

- “Syndrome X”: 3 or more of the following criteria:
  - Waist circumference > 88 cm
  - Triglycerides > 150 mg/dl
  - HDL <50 mg/dl
  - BP > 130/85
  - Fasting glucose >110 mg/dl

- ACOG and ADA suggest screening all women w/ PCOS for glucose intolerance, type 2 DM.

- Oral glucose tolerance test more sensitive than fasting glucose.

- No test of insulin resistance is needed to make diagnosis of PCOS or to select treatment

- Acanthosis nigricans

- Personal or family history of DM
Screen and Test For Long-term Issues

- Lipids
- OGTT
- Polysomnography
- Depression Screen
- Endometrial Biopsy
Screening Recommendations for IGT in PCOS
AE-PCOS Society

- All patients with PCOS, regardless of BMI, should be screened using a 2h OGTT

- Patients with normal glucose tolerance should be rescreened every 2 years or earlier if additional risk factors are identified

- Patients with IGT should be screened annually for DM
PCOS Management

- Body weight loss is associated with beneficial effects on hormones, metabolism and clinical features.

- A further clinical and endocrinological improvement can also be achieved by adding insulin-sensitizing agents and/or antiandrogens to weight reduction programmes.
Diet

- Low in calories with limited carbohydrates, low fat foods, rich source fibrous and protein foods are recommended

- Dietary modification using a low calorie low glycaemic index (GI) diet could specifically reduces some of the health risks associated with PCOS such as endometrial cancer when compared to other diets

- A low GI diet contains carbohydrates that minimise changes in PPG levels and leads to a sustained reduction in hyperinsulinaemia

Egan et al. BMC Research Notes 2011, 4:53
Exercise

- Minimum 5 days a week of 30-40 min brisk walk
- Weight loss of 5-10% of the initial weight improves the endocrine actions (Ovulation, Menstrual cyclicity, fertility)\(^1\)

2. Midland Fertility Services PCOS03 012007.jlaa
New Targets for Therapy in PCOS

- Genetics
- Aging
- Drugs
- Life style
- Central obesity

New Target for Rx

- Insulin Resistance
- Hyperinsulinemia
- Altered steroid and hormones
- PCOS

Traditional Target

- Acne
- Hirustism
- Hyperandrogenism
- Infertility
Management:

- **Insulin resistance**

**Metformin**

- **Function**
  - Lowers hepatic glucose production by reducing gluconeogenesis
  - Increases peripheral glucose uptake by skeletal muscle and adipose tissue
  - Reduces intestinal glucose absorption

- **Outcomes**
  - Estimated 31% reduction in development of type II DM over mean period 3 years
  - Taken during pregnancy, reduction in gestational diabetes and major fetal complications
• The 2013 Endocrine Society guidelines state that Metformin should be reserved for the treatment of women presenting with only menstrual irregularity because it has limited benefits in treating hyperandrogenism associated with PCOS.

• A high prevalence of insulin resistance is noted among the Asians, and these guidelines may not hold good for this population.
Use of metformin in PCOS in Indian population

**Metformin is as effective as OC combination of ethinyl estradiol & Drospirenone in regularizing menstrual cycles, decreasing body mass index, and treating hyperandrogenism in Indian women diagnosed with PCOS**
Cumulative incidence of T2D at 3 years

3234 subjects with IGT

Are Young Adult Women with Polycystic Ovary Syndrome Slipping through the Healthcare Cracks?

Anuja Dokras¹, MD, PhD, Selma Feldman Witchel², MD

JCEM, May 2014
# Information Regarding PCOS

<table>
<thead>
<tr>
<th>Information</th>
<th>North America</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Satisfaction with information about PCOS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissatisfied or indifferent</td>
<td>606 (83.0)</td>
<td>505 (86.9)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>124 (17.0)</td>
<td>76 (13.1)</td>
</tr>
<tr>
<td><strong>Information about lifestyle management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissatisfied or indifferent</td>
<td>316 (43.2)</td>
<td>250 (43.1)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>95 (13.0)</td>
<td>55 (9.5)</td>
</tr>
<tr>
<td>This information was not mentioned</td>
<td>320 (43.8)</td>
<td>275 (47.4)</td>
</tr>
<tr>
<td><strong>Information about medical therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissatisfied or indifferent</td>
<td>406 (55.7)</td>
<td>302 (52.2)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>141 (19.3)</td>
<td>74 (12.8)</td>
</tr>
<tr>
<td>This information was not mentioned</td>
<td>182 (25.0)</td>
<td>203 (35.0)</td>
</tr>
<tr>
<td><strong>Information on long term complications</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissatisfied or indifferent</td>
<td>299 (41.0)</td>
<td>225 (38.9)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>68 (9.3)</td>
<td>30 (5.2)</td>
</tr>
<tr>
<td>This information was not mentioned</td>
<td>363 (49.7)</td>
<td>323 (55.9)</td>
</tr>
<tr>
<td><strong>Emotional support and counselling after diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dissatisfied or indifferent</td>
<td>275 (37.6)</td>
<td>184 (31.8)</td>
</tr>
<tr>
<td>Satisfied</td>
<td>30 (4.1)</td>
<td>10 (1.7)</td>
</tr>
<tr>
<td>This information was not mentioned</td>
<td>426 (58.3)</td>
<td>384 (66.4)</td>
</tr>
</tbody>
</table>
Thank You
Welcome

Let's exchange ideas
REVISITING THE CRITERIA FOR PCOM: should we keep the follicle count or switch to AMH?

Follicles/ovary

Serum AMH

Serum AMH ≥ 35pmol/L (5 ng/mL) was more sensitive than U/S to detect PCOM

Dewailly et al., Hum Reprod, 2011, 26:3123-9
WHICH CAME FIRST: HYPERINSULINAEMIA OR HYPERANDROGENAEMIA?

HYPERINSULINAEMIA IS PRIMARY CONTRIBUTING TO OVARIAN HYPERANDROGENAEMIA

EVIDENCES

1. Pharmacologic reduction of insulin levels in PCOS women improves

2. Reduction of androgen levels by Bilateral Oophorectomy or administration of Gn RH agonist or antiandrogenic compounds in PCOS women has No effect on Insulin Resistance or Hyperinsulinaemia
Management

– Immediate/Acute issues
  – Hirsutism
  – Regulation of menses
  – Fertility issues

– Long-term issues
  – Insulin resistance
  – Cardiovascular risk
  – Obstructive sleep apnea
  – Malignancy risk
Obese women with PCOS tend to be more insulin resistant than normal-wt counterparts.

3-fold increased incidence of metabolic syndrome in PCOS, vs general population, independent of obesity

Obesity is an independent risk factor for glucose intolerance or DM in PCOS

Insulin Resistance in PCOS is Independent of Obesity
Making The Diagnosis

OBESITY

• ½ patients with PCOS are obese

• 80% are hyperinsulinemic and have insulin resistance (independent of obesity)

• 2/3 of patients with PCOS who are not obese have excessive body fat and central adiposity

• Obese patients can be hirsute and/or have menstrual irregularities without having PCOS
Management: Long-Term Issues
Cardiovascular Risk

- HTN
- Dyslipidemia (↑ TG, ↓ HDL, ↑ LDL)
- Predisposition to macrovascular disease and thrombosis

- Nurses’ health study: 20-60% increased risk of CAD events
- Studies of pts undergoing coronary angiography: women with significant h/o hirsutism or polycystic ovaries more likely to have CAD, and if they had it, more extensive CAD, compared to female controls.
Statins in PCOS

- Shown to decrease androgens over and above values induced by OCPs, improve hirsutism, decrease LH and LDL cholesterol, and decrease C-reactive protein and other markers of endothelial activation.

- They also prevented the hypertriglyceridemia induced by OCPs.

- Thus, statins may negate some of the adverse metabolic effects of PCOS and its treatment with OCPs.

Management:
Long-Term Issues

- **Obstructive Sleep Apnea**
  - 30-fold increased risk of OSA, not explained by obesity alone.
  
  - Insulin resistance strongest predictor of OSA (not BMI, age, testosterone)
  
  - Consider polysomnography if at risk
Management:
Long-Term Issues

• **Risk for malignancy**
  – 3X increased risk endometrial carcinoma in PCOS
  – Increased risk of ovarian and breast cancer
  – Warrants regular screening, low threshold for endometrial biopsy
Lifestyle Impact on IR and PCOS

- Insulin receptor expression
- Intracellular AMPK activity
- Increased binding of insulin to insulin receptors
- Increased translocation of GLUT-4
- Insulin sensitivity
- Glucose Uptake

Improves Fertility outcomes and Hyperandrogenemia

Exercise
Metformin mechanism of action in PCOS

- IRS (insulin-receptor substrate proteins) mRNA levels is up-regulated by Metformin

- Metformin was able to substantially enhance the insulin-stimulated translocation of Glut-4 transporters from the cytosol to the membrane.

- Net increase in Glut-4 transporters in the plasma membrane has the potential to increase glucose uptake and metabolism by granulosa cells of the insulin-resistant polycystic ovary, thereby facilitating follicle maturation.

*J Clin Endocrinol Metab. 2011 Jan 5. [Epub ahead of print]*
METFORMIN

- Decreases hepatic glucose production
- Reduces need for insulin secretion
- Improves insulin sensitivity (increases peripheral glucose uptake and utilization)
- Antilipolytic effect—reduces fatty acid concentrations and reduces gluconeogenesis
PCOS - Beginning of Long Term Non-Communicable Diseases
• It is not enough,.......
...to only regularize her periods.....
...or to treat her acne....,
......or to manage her obesity........

it is important for us to put a finger
on what’s ticking behind these
symptoms.
Management:
Regulation of menses

- Lifestyle modification/weight loss

- Metformin- ie., hitting the “root cause”
  500-1000 mg bid, 6 month trial reasonable for improvement of menses

- Oral contraceptives

- Periodic progesterone withdrawal
  Medroxyprogesterone 10 mg/day x 7-10 days, every 3 months (approx 4 menses annually)
FERTILITY - Metformin

500 mg daily

Increase by 500 mg each week until:

- Normal menses (Clinically significant responses not regularly observed at doses less than 1000 mg per day)
- Reached max dose (Target—1500-2550 mg per day)
- Side-effects: Diarrhea, nausea, vomiting, flatulence, indigestion, abdominal discomfort

Minimized by slow increase in dosage
Extended release formulations—fewer side-effects
Entire dose should be given with dinner
Fertility

- Weight loss—reduction in serum testosterone concentration and resumption of ovulation

- Clomiphene: 80% will ovulate, 50% will conceive

- Metformin: when added to clomid, improves ovulatory rates

- FSH injections

- Laparoscopic surgery: wedge resections, laparoscopic ovarian laser electrocautery

- IVF
Laparoscopic Ovarian Drilling (LOD) - Review results

- Surgical ovarian wedge resection was the first established treatment for anovulatory PCOS patients but was largely abandoned due to the risk of post-surgical adhesion formation.

- LOD is accepted as a second-line treatment for clomiphene citrate-resistant anovulatory infertility in PCOS.

- Value as a primary treatment for subfertile patients with anovulation and PCOS is undetermined.

- There is insufficient evidence to determine a difference in ovulation or pregnancy rates when compared to gonadotrophin therapy as a secondary treatment for clomiphene-resistant women.

Pregnancy Complications

• SpontaneousAbortions
  – Increased in high BMI/PCOS patients


• ImpairedGlucose Tolerance

• GestationalDiabetes


• Hypertension


• Small for Gestational Age


Thankyou
Guidelines (RCOG, May 2003)

Evidence based guidelines for reduction of long-term PCOS consequences

1- Patients presenting with PCOS particularly if they are obese, should be offered measurement of fasting blood glucose and urine analysis for glycosuria. Abnormal results should be investigated by a glucose tolerance test.

2- Women who have been diagnosed as having PCOS before pregnancy (eg those requiring ovulation induction for conception) should be screened for gestational diabetes in early pregnancy, with referral to a specialized obstetric diabetic service if abnormalities are detected (evidence level IIb[B])
Guidelines (RCOG, May 2003)

- 3-Measurement of fasting cholesterol, lipids and triglycerides should be offered to patients with PCOS, since early detection of abnormal levels might encourage improvement in diet and exercise (Evidence level III[C])
- 4- Olig- and amenorrhoeic women with PCOS may develop endometrial hyperplasia and later carcinoma. It is good practice to recommend treatment with progestogens to induce withdrawal bleed at least every 3-4 months (Evidence level IIa[B])
5- A body of evidence has accumulated demonstrating safety and in some studies efficacy of insulin-sensitizing agents in the management of short-term complications of PCOS, particularly anovulation. Long-term use of these agents for avoidance of metabolic complications of PCOS can not as yet be recommended (Evidence level IV[B]).

6- No clear consensus has yet emerged concerned regular screening of women with PCOS for later development of diabetes and dyslipidemia but obese women with a strong family history of cardiac disease or diabetes should be assessed regularly in a general practice or hospital outpatient setting. Local protocols should be developed and adapted as new evidence emerges (Evidence level IV[C]).
Pathogenesis: Hyper-androgenism

- Symptoms of androgen excess
- Reduced sex-hormone-binding globulin (SHBG) → more free testosterone
- Insulin insensitivity
- Lipid abnormalities
- Abdominal obesity
Pathogenesis: Insulin resistance

- Favors anovulation, androgen excess, reduced SHBG
- Metabolic syndrome
- Abdominal obesity
HYPERINSULINEMIA

• Excess insulin production and insulin resistance

• ?? Genetic link

• Hyperandrogenism vs. hyperinsulinemia
  – Which came first?
  – Good question without Good answers
1. Hyperandrogenism

- **Laboratory features**
  - Elevated total testosterone
    - Most values in PCOS <150 ng/dl (if >200 ng/dl, consider ovarian or adrenal tumor)
    - Free testosterone assays may not be reliable
  - DHEA-S
    - Most normal or slightly high in PCOS
    - If >800 mcg/dl, consider adrenal tumor
  - LH/FSH ratio
    - Levels vary over menstrual cycle, released in pulsatile fashion, affected by OCPs
    - LH/FSH ratio >2 has little diagnostic sensitivity and need not be documented
TREATMENT—no fertility desired

- Monophasic antiandrogenic OCP
  - ON 1/35 (norethindrone)
  - Orthocyclen (norgestimate)
  - Desogen or Orthocept (desogestrel)
  - Yasmin
Androgens block inhibitory effect of progesterone
INFERTILITY

• Intermittent ovulation or anovulation

• Inherent ovarian disorder—studies show reduced rates of conception despite therapy with Clomiphene
Other issues
Role of epilepsy?

- Increased incidence of reproductive disorders in patients with epilepsy
- Pts on valproic acid may have higher levels of insulin, testosterone, and TG
New things on the horizon…

- **Somatostatin analogs**
  - **Function**
    - Blunts LH response to GnRH
    - Decreases GH secretion by pituitary
    - Inhibits pancreatic insulin release
  - **Outcomes: limited studies**
    - 7 d administration octreotide in PCOS women → decreased fasting and glucose-stimulated insulin levels
    - Reduced LH, androgen, IGF-1 levels
    - Short half-life (80-110 min) requiring multiple injections
    - Extended release octreotide (octreotide-LAR)- inject IM Q28 days- results in improvement in GH, insulin, IGF-1, hirsutism
    - Not approved yet
Ghrelin and PCOS

• Dysregulation of ghrelin levels may lead to physiological problems including obesity and polycystic ovary syndrome (PCOS).

• A study was done to compare ghrelin levels in women with and without PCOS.

• Serum ghrelin levels (pre- and post-prandial) were compared between 30 Saudi women suffering from PCOS and 30 healthy controls.

No relationship between circulating ghrelin levels and the abnormal hormonal pattern of the PCOS were observed.
Classifications of evidence levels

- **Ia:** Evidence obtained from meta-analysis of randomized controlled trials
- **Ib:** Evidence obtained from at least one randomized controlled trial
- **IIa:** Evidence obtained from at least one well-designed controlled study without randomization
- **IIb:** Evidence obtained from at least one other type of well-designed quasi-experimental study
- **III:** Evidence obtained from well-designed non-experimental descriptive studies, such as comparative studies, correlation studies and case studies
- **IV:** Evidence obtained from expert committee reports or opinions and/or clinical experience of respected authorities
Grades of Recommendations

• **A** - Requires at least one randomized controlled trial as part of a body of literature of overall good quality and consistency addressing the specific recommendation. (Evidence levels Ia, Ib)

• **B** - Requires the availability of well controlled clinical studies but no randomized clinical trials on the topic of recommendations (Evidence levels IIa, IIb, III)

• **C** - Requires evidence obtained from expert committee reports or opinions and/ or clinical experiences of respected authorities. Indicates an absence of directly applicable clinical studies of good quality. (Evidence level IV)
Abnormal Pituitary Function—Altered Negative Feedback Loop

- Increased GnRH from hypothalamus
- Excessive LH secretion relative to FSH by pituitary gland
- LH stimulates ovarian thecal cells → androgen production
- Ineffective suppression of the LH pulse frequency by estradiol and progesterone
- Androgen excess increases LH by blocking the hypothalamic inhibitory feedback of progesterone
Rotterdam Criteria (2 out of 3)

- Menstrual irregularity
due to anovulation oligo-ovulation

- Evidence of clinical or biochemical hyperandrogenism

- Polycystic ovaries by USG
  - presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter and/or increased ovarian volume
SIDE EFFECTS

• Lactic acidosis—rare
  – Avoid in CHF, renal insufficiency, sepsis
  – Discontinue for procedures using contrast (withhold X 48 hours)
  – Temporarily suspend for all surgical procedures that involve fluid restriction
  – Cimetidine causes increased metformin levels
PCOS: Patho-physiology

- Insulin Resistance
- Hyper-Insulinemia
- LH/FSH Dominance
- LH Effect on Theca cells of follicles
- Abdominal Fat
- Aromatase activity

- Liver
- SHBG
- Free androgens
- Follicular Arrest
- Cyst Formation
- Formation of androgen and estrogen

References:
Abnormal steroidogenenesis

- Intraovarian androgen excess results in excessive growth of small ovarian follicles
- Excess androgen causes thecal and stromal hyperplasia
- Follicular maturation is inhibited
- Reduction in ovulatory events leads to deficient progesterone secretion
- Chronic estrogen stimulation of the endometrium with no progesterone for differentiation—intermittent breakthrough bleeding or DUB
PCOS-
More Than A Reproductive Issue

Dr. Piya Ballani Thakkar
Diplomate of the American Board of Endocrinology, Diabetes, & Metabolism
FACE
Diplomate of the American Board of Int. Medicine
M.D. - Ob/ Gyn (Mumbai), D.N.B., D.G.O., F.C.P.S.

-------------------
Consultant Endocrinologist
Bombay Hospital and Medical Research Center
Insulin resistance
Central obesity

Endocrine manifestations

†Insulin
Liver
†Sex hormone binding globulin
Ovary

†Androgen activity
Adrenal gland

Clinical presentation
Infertility
Menstrual disturbance
Hirsutism

Metabolic manifestations
Glucose intolerance
Hypertension
Dyslipidaemia

Long term sequelae
Vascular disease
Conclusion

✓ Treatment of IGT is required
✓ LSM as a medication Must
✓ LSM may not be possible for everyone
✓ LSM may not work for everyone
✓ Medication is required
✓ Ideal not available
✓ Metformin, etc are adjuvant
✓ Lifestyle is the best preventive vaccine